Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FOURTH QUARTER CONSOLIDATED REVENUES OF $2.80 BILLION, UP 9% ON A REPORTED BASIS AND UP 6% ON AN ORGANIC (NON-GAAP) 1 BASIS OVER THE PRIOR YEAR PERIOD FULL-YEAR CONSOLIDATED REVENUES OF $10.27BILLION, UP 7% ON A REPORTED BASIS AND 5% ON AN ORGANIC (NON-GAAP)1 BASIS GAAP NET LOSS ATTRIBUTABLE TO BAUSCH HEALTH OF $112 MILLION FOR THE QUARTER AND GAAP NET INCOME ATTRIBUTABLE TO BAUSCH HEALTH OF $157 MILLION FOR THE YEAR CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $1.05 BILLION FOR THE QUARTER, UP 13%, AND $3.54 BILLION FOR THE YEAR, UP 7% BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FOURTH QUARTER AND FULL-YEAR 2025 RESULTS DELIVERED ELEVENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH IN BOTH REVENUE AND ADJUSTED EBITDA (NON-GAAP)1, EXCEEDING 2025 GUIDANCE ON ALL METRICS COMPLETED THE ACQUISITION OF SHIBO'S FULLSERVICE AESTHETICS DISTRIBUTION BUSINESS IN CHINA ON DECEMBER 1, 2025 EXECUTED A $1.7 BILLION DEBT EXCHANGE OFFER DURING THE FOURTH QUARTER AND $9.6 BILLION IN TOTAL REFINANCING FOR THE FULL-YEAR 2025, EXTENDING NEAR- AND MEDIUM-TERM MATURITIES GENERATED $362 MILLION IN ADJUSTED CASH FLOW FROM OPERATIONS (NON-GAAP)1 IN THE FOURTH QUARTER AND $1.2 BILLION FOR THE FULL-YEAR 2025 LAVAL, QC, FEB. 18, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" THE "COMPANY," "WE" OR "OUR") TODAY ANNOUNCED ITS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND OTHER KEY UPDATES FOR THE QUARTER. "THE FOURTH QUARTER MARKS OUR ELEVENTH CONSECUTIVE QUARTER OF YEAROVERYEAR GROWTH IN REVENUE AND ADJUSTED EBITDA FOR BAUSCH HEALTH, EXCLUDING BAUSCH + LOMB.

BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS

LAVAL, QC, FEB. 17, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT EXECUTIVE VICE PRESIDENT AND CFO JEAN-JACQUES (JJ) CHARHON, ALONG WITH OTHER MANAGEMENT TEAM MEMBERS, WILL ATTEND THE J.P. MORGAN GLOBAL LEVERAGED FINANCE CONFERENCE IN MIAMI BEACH, FLORIDA, FROM MARCH 24, 2026, TO MEET WITH INVESTORS.

BAUSCH HEALTH TO PARTICIPATE IN THE J.P. MORGAN GLOBAL LEVERAGED FINANCE CONFERENCE

BAUSCH HEALTH TO PROVIDE SCHOLARSHIPS TO 10 STUDENTS LIVING WITH GI DISEASES LAVAL, QC, FEB. 11, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE: BHC)(TSX: BHC) AND ITS GASTROENTEROLOGY (GI) BUSINESS, SALIX PHARMACEUTICALS ("SALIX"), TODAY ANNOUNCED THE OPENING OF THE 2026 SALIX GASTROINTESTINAL HEALTH SCHOLARS PROGRAM APPLICATION PERIOD. THE PROGRAM WILL AWARD 10 EXCEPTIONAL STUDENTS LIVING WITH GI DISEASE A SCHOLARSHIP OF UP TO $10,000 AS THEY WORK TO PURSUE THEIR HIGHER EDUCATION GOALS.

BAUSCH HEALTH ANNOUNCES 2026 GASTROINTESTINAL HEALTH SCHOLARS PROGRAM

LAVAL, QC, JAN. 23, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), TODAY ANNOUNCED THE RESULTS OF THE GLOBAL PHASE 3RED-C CLINICAL PROGRAM EVALUATING AMORPHOUS-RIFAXIMIN SOLID SOLUBLE DISPERSION (SSD) IN ADULTS WITH LIVER CIRRHOSIS FOR THE PRIMARY PREVENTION OF HEPATIC ENCEPHALOPATHY (HE). WHILE SAFE AND WELL-TOLERATED, BOTH CLINICAL TRIALS DID NOT MEET THE PRIMARY ENDPOINT.

BAUSCH HEALTH PROVIDES UPDATE ON RED-C PHASE 3 CLINICAL TRIALS

LAVAL,QC, JAN. 21, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) WILL RELEASE FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AFTER MARKET CLOSE ON WEDNESDAY, FEBRUARY 18, 2026. BAUSCH HEALTH WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 5:00 P.M.

BAUSCH HEALTH TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2025 RESULTS ON FEBRUARY 18, 2026

LAVAL, QC, JAN. 5, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), TODAY ANNOUNCED THAT THOMAS J. APPIO, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE AT THE 44TH ANNUAL J.P.

BAUSCH HEALTH TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

LAVAL, QC / ACCESS NEWSWIRE / DECEMBER 23, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) (THE "COMPANY") AND ITS SUBSIDIARY 1261229 B.C. LTD. (THE "ISSUER" AND, TOGETHER WITH THE COMPANY, THE "OFFERORS") TODAY ANNOUNCED THE FINAL RESULTS AND EXPIRATION OF THEIR PREVIOUSLY ANNOUNCED OFFERS TO EXCHANGE THE COMPANY'S OUTSTANDING 4.875% SENIOR SECURED NOTES DUE 2028 (THE "4.875% NOTES") AND 11.00% SENIOR SECURED NOTES DUE 2028 (THE "11.00% NOTES" AND TOGETHER WITH THE 4.875% NOTES, THE "EXISTING SENIOR SECURED NOTES") FOR UP TO $1.6 BILLION AGGREGATE PRINCIPAL AMOUNT OF THE ISSUER'S 10.00% SENIOR SECURED NOTES DUE 2032 (THE "NEW NOTES" AND, SUCH OFFERS, THE "OFFERS") , IN EACH CASE, PURSUANT TO THE TERMS DESCRIBED IN A CONFIDENTIAL EXCHANGE OFFER MEMORANDUM DATED NOVEMBER 24, 2025 (THE "EXCHANGE OFFER MEMORANDUM").

BAUSCH HEALTH ANNOUNCES FINAL RESULTS AND EXPIRATION OF EXCHANGE OFFERS

LAVAL, QC / ACCESS NEWSWIRE / DECEMBER 8, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) (THE "COMPANY") ANNOUNCED TODAY THE RESULTS TO DATE OF ITS PREVIOUSLY ANNOUNCED OFFERS TO EXCHANGE THE COMPANY'S OUTSTANDING 4.875% SENIOR SECURED NOTES DUE 2028 (THE "4.875% NOTES") AND 11.00% SENIOR SECURED NOTES DUE 2028 (THE "11.00% NOTES" AND TOGETHER WITH THE 4.875% NOTES, THE "EXISTING SENIOR SECURED NOTES") FOR UP TO $1.6 BILLION AGGREGATE PRINCIPAL AMOUNT (THE "MAXIMUM NOTES AMOUNT") OF NEW 10.00% SENIOR SECURED NOTES DUE 2032 (THE "NEW NOTES" AND, SUCH OFFERS, THE "OFFERS") TO BE ISSUED BY THE COMPANY'S INDIRECT WHOLLY-OWNED SUBSIDIARY 1261229 B.C. LTD. (TOGETHER WITH THE COMPANY, THE "OFFERORS"), IN EACH CASE, PURSUANT TO THE TERMS DESCRIBED IN A CONFIDENTIAL EXCHANGE OFFER MEMORANDUM DATED NOVEMBER 24, 2025 (THE "EXCHANGE OFFER MEMORANDUM").

BAUSCH HEALTH ANNOUNCES EARLY EXCHANGE OFFER RESULTS FOR EXCHANGE OFFERS

TRANSACTION BOOSTS SOLTA MEDICAL'S POSITION TO MEET RISING DEMAND IN CHINA'S GROWING AESTHETICS MARKET LAVAL, QC / ACCESS NEWSWIRE / DECEMBER 1, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, ALONG WITH ITS GLOBAL AESTHETIC BUSINESS, SOLTA MEDICAL, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF THE ACQUISITION OF WUHAN SHIBO ZHENMEI TECHNOLOGY CO., LTD., CONSISTING OF THE SHIBO GROUP'S AESTHETICS DISTRIBUTION BUSINESS.

BAUSCH HEALTH'S AESTHETICS BUSINESS, SOLTA MEDICAL, ACQUIRES LONGTIME DISTRIBUTION PARTNER, THE SHIBO GROUP, TO STRENGTHEN PRESENCE IN CHINA

LAVAL, QC / ACCESS NEWSWIRE / NOVEMBER 24, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) (THE "COMPANY" OR "BAUSCH HEALTH") TODAY ANNOUNCED THE COMMENCEMENT OF OFFERS TO EXCHANGE THE COMPANY'S OUTSTANDING 4.875% SENIOR SECURED NOTES DUE 2028 (THE "4.875% NOTES") AND 11.00% SENIOR SECURED NOTES DUE 2028 (THE "11.00% NOTES" AND TOGETHER WITH THE 4.875% NOTES, THE "EXISTING SENIOR SECURED NOTES") FOR UP TO $1.6 BILLION AGGREGATE PRINCIPAL AMOUNT (THE "MAXIMUM NOTES AMOUNT") OF NEW 10.00% SENIOR SECURED NOTES DUE 2032 (THE "NEW NOTES" AND, SUCH OFFERS, THE "OFFERS") ISSUED BY 1261229 B.C. LTD., THE COMPANY'S INDIRECT WHOLLY-OWNED SUBSIDIARY (THE "ISSUER" AND, TOGETHER WITH THE COMPANY, THE "OFFERORS"), IN EACH CASE, PURSUANT TO THE TERMS DESCRIBED IN A CONFIDENTIAL EXCHANGE OFFER MEMORANDUM DATED NOVEMBER 24, 2025 (THE "EXCHANGE OFFER MEMORANDUM").

BAUSCH HEALTH ANNOUNCES LAUNCH OF OFFERS TO EXCHANGE CERTAIN EXISTING SENIOR SECURED NOTES

LAVAL, QC / ACCESS NEWSWIRE / NOVEMBER 18, 2025 / BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), TODAY ANNOUNCED THAT JEAN-JACQUES CHARHON, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE IN CORAL GABLES, FLORIDA ON DECEMBER 2, 2025. A LIVE AUDIO WEBCAST OF THE EVENT WILL BE ACCESSIBLE ON THE INVESTOR RELATIONS SECTION OF BAUSCH HEALTH'S WEBSITE.

BAUSCH HEALTH TO PARTICIPATE IN THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, WILL OUTLINE THE NEXT CHAPTER OF ITS EVOLUTION TODAY DURING AN INVESTOR DAY EVENT AT THE NEW YORK STOCK EXCHANGE. LEADING THROUGH REINVENTION OVER THE PAST FEW YEARS, BAUSCH + LOMB HAS UNDERGONE A COMPLETE TRANSFORMATION BY REDEFINING HOW IT OPERATES. THE COMPANY HAS SHARPENED ITS FOCUS THROUGH SIMPLIFICATION, REBUILT ITS CULTU.

Bausch Health Companies Inc.

BHC

Price

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHC